Skip to main content

Table 2 Patient characteristics

From: Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

Breed

Age (years)

Body weight (kg)

Clinical stage (TNM)ϕ

Number of tumors

Parturition

ERα

Standard scheme (Dox)

Standard Poodle

12

6

III

2

0

Positive

Maltese bichon

9

9.9

III

7

2

Positive

Dachshund

13

6.6

III

4

2

Positive

Maltese bichon

7

6.6

III

5

0

Positive

Standard scheme (Dox + I2)

Rottweiler

8

38

III

1

2

Positive

Standard Poodle

12

5.8

II

5

0

Positive

Standard Poodle

10

3.8

III

5

0

Positive

Labrador Retriever

10

30

III

7

0

Positive

Standard Poodle

12

6.4

V

8

1

Positive

Standard Poodle

9

7

III

9

1

Positive

Modified scheme (Dox)

Cocker Spaniel

9

10.3

II

8

0

Positive

Mixed breed

6

4.2

II

2

0

Positive

Cocker Spaniel

8

13

I

6

3

Positive

Chihuahua

5

2.2

I

3

0

Positive

German Shepherd

7

30.1

III

7

0

Positive

Dalmatian

6

23

I

1

0

Positive

Modified scheme (Dox + I2)

Cocker Spaniel

10

16.8

III

1

0

Positive

Mixed breed

8

7.6

I

5

0

Positive

Standard Poodle

11

4.2

V

7

0

Positive

Cocker Spaniel

13

9.8

III

7

0

Positive

Fox terrier Toy

7

2.4

I

5

0

Positive

Standard Poodle

10

4.5

III

3

0

Positive

Cocker Spaniel

13

17.4

III

7

3

Positive

Standard Poodle

10

6

II

8

0

Positive

Standard Poodle

9

4.7

III

6

4

Positive

Chihuahua

5

3.8

III

5

0

Positive

Dachshund

10

5.2

III

5

1

Positive

  1. ϕ T – Primary tumor, N – Regional lymph nodes, M – Distant metastasis [28];
  2. Bold numbers, overweight animals (10–30% of standard weight)